{
    "hands_on_practices": [
        {
            "introduction": "Clinical guidelines are built upon a solid foundation of evidence. This first practice invites you to step into the role of a clinical researcher by working with data representative of major clinical trials . By calculating fundamental metrics such as relative risk and the number needed to treat, you will gain a firsthand understanding of how the significant benefits of antenatal corticosteroids are quantified, translating raw data into clinically meaningful conclusions.",
            "id": "4402837",
            "problem": "Antenatal corticosteroids (ACS) administered to pregnant individuals at risk of preterm birth between $28$ and $34$ weeks are widely used to accelerate fetal lung maturation and reduce neonatal Respiratory Distress Syndrome (RDS). Consider a meta-analytic aggregation of randomized trials in singleton pregnancies, stratified by gestational age windows. Across included studies, the following total RDS event counts and denominators were obtained for ACS versus control:\n\n- For $28$–$30$ weeks: control had $e_{c1} = 270$ events among $n_{c1} = 520$ neonates; ACS had $e_{t1} = 170$ events among $n_{t1} = 510$ neonates.\n- For $31$–$34$ weeks: control had $e_{c2} = 220$ events among $n_{c2} = 980$ neonates; ACS had $e_{t2} = 140$ events among $n_{t2} = 960$ neonates.\n\nUsing only foundational definitions of probability and risk in populations, compute the pooled control event rate $r_{c}$ and pooled treated event rate $r_{t}$ for RDS across $28$–$34$ weeks, then derive the absolute risk reduction (ARR), the relative risk (RR), and the Number Needed to Treat (NNT) to prevent one RDS case. Round each of the five quantities to four significant figures. Express all quantities as decimals with no units and do not use the percentage sign.",
            "solution": "The user has provided a problem asking for the calculation of several biostatistical measures of effect from pooled meta-analytic data on antenatal corticosteroids (ACS) for fetal lung maturation.\n\nFirst, a validation of the problem statement is required.\n\n**Step 1: Extract Givens**\n- Stratum 1 ($28$–$30$ weeks gestational age):\n  - Control group: $e_{c1} = 270$ Respiratory Distress Syndrome (RDS) events among $n_{c1} = 520$ neonates.\n  - ACS group: $e_{t1} = 170$ RDS events among $n_{t1} = 510$ neonates.\n- Stratum 2 ($31$–$34$ weeks gestational age):\n  - Control group: $e_{c2} = 220$ RDS events among $n_{c2} = 980$ neonates.\n  - ACS group: $e_{t2} = 140$ RDS events among $n_{t2} = 960$ neonates.\n- Required calculations:\n  1. Pooled control event rate, $r_c$.\n  2. Pooled treated event rate, $r_t$.\n  3. Absolute risk reduction, ARR.\n  4. Relative risk, RR.\n  5. Number Needed to Treat, NNT.\n- Rounding instruction: Round each of the five quantities to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem is based on a well-established clinical intervention (ACS for fetal lung maturity) and standard epidemiological methods (pooling data, calculating risk metrics). The context and data are scientifically sound and realistic.\n- **Well-Posed:** All necessary data ($e_{c1}, n_{c1}, e_{t1}, n_{t1}, e_{c2}, n_{c2}, e_{t2}, n_{t2}$) are provided to calculate the requested metrics. The definitions of ARR, RR, and NNT are standard and allow for a unique solution.\n- **Objective:** The problem is stated with precise, objective data and terminology. It does not contain subjective or opinion-based claims.\n- The problem is free from the flaws listed in the instructions (e.g., it is not contradictory, incomplete, or based on false premises). Specifically, for all groups, the number of events is less than or equal to the number of subjects (e.g., $e_{c1} \\le n_{c1}$).\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Solution Derivation**\n\nThe problem requires pooling the data from the two gestational age strata to calculate overall measures of effect.\n\n1.  **Pooled Control Event Rate ($r_c$)**\n    The pooled control event rate is the total number of events in both control strata divided by the total number of subjects in both control strata.\n    Total control events: $E_c = e_{c1} + e_{c2} = 270 + 220 = 490$.\n    Total control subjects: $N_c = n_{c1} + n_{c2} = 520 + 980 = 1500$.\n    The pooled control event rate is therefore:\n    $$r_c = \\frac{E_c}{N_c} = \\frac{490}{1500} = 0.32666...$$\n    Rounding to four significant figures, we get $r_c \\approx 0.3267$.\n\n2.  **Pooled Treated Event Rate ($r_t$)**\n    Similarly, the pooled treated event rate is the total number of events in both ACS strata divided by the total number of subjects in both ACS strata.\n    Total treated events: $E_t = e_{t1} + e_{t2} = 170 + 140 = 310$.\n    Total treated subjects: $N_t = n_{t1} + n_{t2} = 510 + 960 = 1470$.\n    The pooled treated event rate is therefore:\n    $$r_t = \\frac{E_t}{N_t} = \\frac{310}{1470} = 0.21088435...$$\n    Rounding to four significant figures, we get $r_t \\approx 0.2109$.\n\n3.  **Absolute Risk Reduction (ARR)**\n    The ARR is the absolute difference between the event rate in the control group and the event rate in the treated group. It is defined as:\n    $$\\text{ARR} = r_c - r_t$$\n    Using the unrounded values for higher precision in intermediate steps:\n    $$\\text{ARR} = \\frac{490}{1500} - \\frac{310}{1470} = 0.32666... - 0.21088435... = 0.11578231...$$\n    Rounding to four significant figures, we get $\\text{ARR} \\approx 0.1158$.\n\n4.  **Relative Risk (RR)**\n    The RR is the ratio of the event rate in the treated group to the event rate in the control group. It is defined as:\n    $$\\text{RR} = \\frac{r_t}{r_c}$$\n    Using the unrounded values for precision:\n    $$\\text{RR} = \\frac{310/1470}{490/1500} = \\frac{0.21088435...}{0.32666...} = 0.6455646...$$\n    This indicates that the risk of RDS in the ACS-treated group is approximately $64.56\\%$ of the risk in the control group.\n    Rounding to four significant figures, we get $\\text{RR} \\approx 0.6456$.\n\n5.  **Number Needed to Treat (NNT)**\n    The NNT is the reciprocal of the Absolute Risk Reduction. It represents the average number of patients who need to be treated to prevent one additional bad outcome.\n    $$\\text{NNT} = \\frac{1}{\\text{ARR}}$$\n    Using the unrounded ARR for precision:\n    $$\\text{NNT} = \\frac{1}{0.11578231...} = 8.636758...$$\n    Rounding to four significant figures, we get $\\text{NNT} \\approx 8.637$. This means one case of RDS is prevented for approximately every $9$ individuals treated with ACS in this population.\n\nThe five requested quantities, rounded to four significant figures, are:\n- $r_c = 0.3267$\n- $r_t = 0.2109$\n- $\\text{ARR} = 0.1158$\n- $\\text{RR} = 0.6456$\n- $\\text{NNT} = 8.637$",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.3267 & 0.2109 & 0.1158 & 0.6456 & 8.637 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Effective treatment requires more than just the right drug; it demands correct delivery. This is particularly true for intramuscular injections in patients with an elevated Body Mass Index (BMI), where subcutaneous fat can prevent medication from reaching the target muscle. This exercise  challenges you to integrate principles from biomechanics and statistics to solve a practical clinical problem: selecting the proper needle length to ensure true intramuscular delivery. Mastering this skill is crucial for guaranteeing that the proven benefits of corticosteroids are actually realized in all patients.",
            "id": "4402897",
            "problem": "A pregnant patient at $30$ weeks of gestation with a high Body Mass Index (BMI) of $43\\,\\text{kg}\\,\\text{m}^{-2}$ is indicated to receive antenatal corticosteroids, which are administered by intramuscular (IM) injection. To ensure true IM delivery at the ventrogluteal site, you plan to select a needle length based on a point-of-care ultrasound measurement of the skin-to-superficial-muscle fascia distance at rest. The ultrasound reports a resting skin-to-fascia distance of $s_{0} = 34\\,\\mathrm{mm}$, with Gaussian measurement uncertainty characterized by a standard deviation $u_{s} = 1.2\\,\\mathrm{mm}$.\n\nFor modeling tissue mechanics and injection geometry, use the following well-tested approximations:\n\n- The total resting skin-to-fascia distance $s_{0}$ consists of an incompressible component from skin and superficial fascia totaling $e+f = 4\\,\\mathrm{mm}$ and a compressible subcutaneous adipose thickness $a_{0} = s_{0} - (e+f)$.\n- Firm, steady pressure applied before needle insertion compresses only the adipose layer by a fraction $\\beta$, where $\\beta = \\min\\{\\alpha\\,\\sigma,\\,\\beta_{\\max}\\}$. Here $\\sigma$ is the applied normal stress, $\\alpha$ is the adipose compressibility coefficient, and $\\beta_{\\max}$ is the cap on compressibility.\n- The operator applies a normal force $F = 12\\,\\mathrm{N}$ over a contact area $A = 4.0\\,\\text{cm}^2$, the adipose compressibility coefficient is $\\alpha = 0.004\\,\\text{kPa}^{-1}$, and the compressibility cap is $\\beta_{\\max} = 0.30$.\n- The injection may deviate from the skin normal by up to an angle $\\theta = 20^\\circ$, increasing the path length through the soft tissues by a factor $1/\\cos(\\theta)$.\n- To ensure a reliable intramuscular depot, require a minimum intramuscular penetration of $p_{\\min} = 5\\,\\mathrm{mm}$ beyond the muscle fascia.\n- For safety, the operator will not seat the needle fully to the hub; instead, they will leave $h = 2\\,\\mathrm{mm}$ of the needle uninserted.\n\nUsing the above, design for $95\\%$ reliability against measurement uncertainty by first replacing $s_{0}$ with the $95^{\\mathrm{th}}$ percentile of the Gaussian measurement model. Then compute the minimal needle length $L_{\\min}$ that guarantees at least $p_{\\min}$ intramuscular penetration when accounting for adipose compression and the maximum angular deviation $\\theta$. Express the final needle length in millimeters and round your answer to three significant figures. State your final value in millimeters (mm). Angles are in degrees.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, objective, and contains sufficient information for a unique solution.\n\n### Step 1: Extract Givens\n- Resting skin-to-fascia distance (mean): $s_{0} = 34\\,\\mathrm{mm}$\n- Standard deviation of measurement uncertainty: $u_{s} = 1.2\\,\\mathrm{mm}$\n- Measurement uncertainty model: Gaussian\n- Incompressible tissue thickness (skin and fascia): $e+f = 4\\,\\mathrm{mm}$\n- Resting subcutaneous adipose thickness: $a_{0} = s_{0} - (e+f)$\n- Applied normal force: $F = 12\\,\\mathrm{N}$\n- Contact area: $A = 4.0\\,\\text{cm}^2$\n- Adipose compressibility coefficient: $\\alpha = 0.004\\,\\text{kPa}^{-1}$\n- Maximum adipose compressibility fraction: $\\beta_{\\max} = 0.30$\n- Adipose compression fraction model: $\\beta = \\min\\{\\alpha\\,\\sigma,\\,\\beta_{\\max}\\}$, where $\\sigma$ is the applied normal stress.\n- Maximum needle deviation from normal: $\\theta = 20^\\circ$\n- Minimum required intramuscular penetration: $p_{\\min} = 5\\,\\mathrm{mm}$\n- Uninserted needle length (safety margin): $h = 2\\,\\mathrm{mm}$\n- Reliability requirement: design for the $95^{\\mathrm{th}}$ percentile of the measurement distribution.\n- Required output: minimal needle length $L_{\\min}$ in millimeters, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, employing simplified but reasonable models from biomechanics (tissue compression) and physics (stress). The given values are clinically plausible for a pregnant patient with a high BMI. The problem is well-posed, providing all necessary parameters and a clear objective. The language is objective and quantitative. The problem does not violate any of the invalidity criteria. It is a formalizable and solvable problem in biomedical engineering.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A step-by-step solution will be provided.\n\n### Solution Derivation\n\nThe goal is to determine the minimum needle length, $L_{\\min}$, that ensures a minimum intramuscular penetration, $p_{\\min}$, under worst-case conditions for tissue depth, injection angle, and accounting for tissue compression and a safety margin.\n\n1.  **Determine the Design Skin-to-Fascia Distance ($s_{95}$)**\n    The problem specifies designing for $95\\%$ reliability by using the $95^{\\mathrm{th}}$ percentile of the Gaussian measurement distribution. The distribution has a mean $\\mu = s_0 = 34\\,\\mathrm{mm}$ and a standard deviation $\\sigma_{dist} = u_s = 1.2\\,\\mathrm{mm}$. The $z$-score for the $95^{\\mathrm{th}}$ percentile of a standard normal distribution is approximately $z \\approx 1.645$.\n    The design distance, $s_{95}$, is therefore:\n    $$s_{95} = \\mu + z \\cdot \\sigma_{dist} = s_{0} + 1.645 \\, u_{s}$$\n    $$s_{95} = 34\\,\\mathrm{mm} + 1.645 \\times 1.2\\,\\mathrm{mm} = 34\\,\\mathrm{mm} + 1.974\\,\\mathrm{mm} = 35.974\\,\\mathrm{mm}$$\n    This is the effective resting skin-to-fascia distance we will use for the remainder of the calculation.\n\n2.  **Calculate the Applied Stress ($\\sigma$) and Adipose Compression ($\\beta$)**\n    The normal stress $\\sigma$ applied to the tissue is the force $F$ divided by the area $A$. We must ensure consistent units. The compressibility coefficient $\\alpha$ is given in $\\text{kPa}^{-1}$, so we will convert the stress to kilopascals (kPa).\n    $$A = 4.0\\,\\text{cm}^2 = 4.0 \\times (10^{-2}\\,\\text{m})^2 = 4.0 \\times 10^{-4}\\,\\text{m}^2$$\n    $$\\sigma = \\frac{F}{A} = \\frac{12\\,\\mathrm{N}}{4.0 \\times 10^{-4}\\,\\text{m}^2} = 30000\\,\\text{N/m}^2 = 30000\\,\\text{Pa} = 30\\,\\text{kPa}$$\n    Now, we calculate the term $\\alpha \\sigma$:\n    $$\\alpha \\sigma = (0.004\\,\\text{kPa}^{-1}) \\times (30\\,\\text{kPa}) = 0.12$$\n    The compression fraction $\\beta$ is the minimum of this value and the maximum allowed compression $\\beta_{\\max}$:\n    $$\\beta = \\min\\{\\alpha\\,\\sigma,\\,\\beta_{\\max}\\} = \\min\\{0.12,\\,0.30\\} = 0.12$$\n\n3.  **Calculate the Compressed Skin-to-Fascia Distance ($s_c$)**\n    The compression only affects the subcutaneous adipose layer. First, we find the resting thickness of this layer, $a_{0}$, using our design distance $s_{95}$.\n    $$a_{0} = s_{95} - (e+f) = 35.974\\,\\mathrm{mm} - 4\\,\\mathrm{mm} = 31.974\\,\\mathrm{mm}$$\n    The thickness of the adipose layer under compression, $a_c$, is reduced by the fraction $\\beta$:\n    $$a_c = a_{0} (1 - \\beta) = 31.974\\,\\mathrm{mm} \\times (1 - 0.12) = 31.974\\,\\mathrm{mm} \\times 0.88 = 28.13712\\,\\mathrm{mm}$$\n    The total skin-to-fascia distance under compression, $s_c$, is the sum of the compressed adipose thickness and the incompressible layer thickness:\n    $$s_c = a_c + (e+f) = 28.13712\\,\\mathrm{mm} + 4\\,\\mathrm{mm} = 32.13712\\,\\mathrm{mm}$$\n\n4.  **Calculate the Minimum Required Needle Length ($L_{\\min}$)**\n    The needle must traverse the compressed tissue layer at an angle, penetrate the muscle, and account for the uninserted length. The worst-case path length through the compressed tissue occurs at the maximum angle of deviation, $\\theta = 20^\\circ$. The path length, $d_{\\text{tissue}}$, required to pass through the vertical distance $s_c$ is:\n    $$d_{\\text{tissue}} = \\frac{s_c}{\\cos(\\theta)}$$\n    The total required travel distance for the needle tip, $L_{\\text{travel}}$, from the skin surface to the final target depth is the sum of the path through the tissue and the required intramuscular penetration depth, $p_{\\min}$.\n    $$L_{\\text{travel}} = d_{\\text{tissue}} + p_{\\min} = \\frac{s_c}{\\cos(\\theta)} + p_{\\min}$$\n    The total needle length $L_{\\min}$ must be sufficient to provide this travel distance, plus the uninserted safety margin $h$.\n    $$L_{\\min} = L_{\\text{travel}} + h = \\frac{s_c}{\\cos(\\theta)} + p_{\\min} + h$$\n    Substituting the known values:\n    $$L_{\\min} = \\frac{32.13712\\,\\mathrm{mm}}{\\cos(20^\\circ)} + 5\\,\\mathrm{mm} + 2\\,\\mathrm{mm}$$\n    Using the value $\\cos(20^\\circ) \\approx 0.9396926$:\n    $$L_{\\min} \\approx \\frac{32.13712}{0.9396926} + 7\\,\\mathrm{mm}$$\n    $$L_{\\min} \\approx 34.20063\\,\\mathrm{mm} + 7\\,\\mathrm{mm} = 41.20063\\,\\mathrm{mm}$$\n\n5.  **Final Answer Rounding**\n    The problem requires the final answer to be rounded to three significant figures.\n    $$L_{\\min} \\approx 41.2\\,\\mathrm{mm}$$",
            "answer": "$$\n\\boxed{41.2}\n$$"
        },
        {
            "introduction": "The art of medicine often lies in making sound decisions with incomplete information. This final practice moves into the realm of clinical judgment by formalizing the trade-offs involved in administering corticosteroids when preterm delivery is uncertain . You will use a decision analysis model to weigh the potential benefits against the potential harms, ultimately calculating the 'break-even' probability of delivery that justifies treatment. This exercise equips you with a powerful framework for navigating clinical uncertainty and making rational, patient-centered choices.",
            "id": "4402924",
            "problem": "A clinician is considering administering a single course of antenatal corticosteroids to a pregnant patient at $31$ weeks with a suspected risk of preterm delivery. Evidence shows that the preventive effect of antenatal corticosteroids on severe neonatal outcomes is time-sensitive, with most benefit realized if the infant is born within $7$ days of treatment. The clinician aims to decide whether to treat now, using an expected utility framework under uncertainty.\n\nUse the following scientifically plausible and self-consistent data:\n\n- If delivery occurs within $7$ days of corticosteroid administration, the relative risk reductions for three severe neonatal outcomes are:\n  - Severe neonatal respiratory morbidity (requiring mechanical ventilation or surfactant): baseline risk $0.30$, relative risk $0.65$ if treated within $7$ days.\n  - Grade III/IV intraventricular hemorrhage (IVH): baseline risk $0.05$, relative risk $0.55$ if treated within $7$ days.\n  - Neonatal death: baseline risk $0.04$, relative risk $0.70$ if treated within $7$ days.\n\n- When antenatal corticosteroids are given but delivery does not occur within $7$ days (so the exposure is unnecessary relative to the optimal window), clinically relevant adverse outcomes have the following absolute risk increases:\n  - Neonatal hypoglycemia: absolute risk increase $0.08$.\n  - Maternal hyperglycemia requiring temporary insulin therapy: absolute risk increase $0.06$.\n  - Clinical chorioamnionitis: absolute risk increase $0.02$.\n\n- Assign severity weights representing expected utility loss per occurrence for each outcome:\n  - Severe neonatal respiratory morbidity: weight $1.0$.\n  - Grade III/IV IVH: weight $3.0$.\n  - Neonatal death: weight $5.0$.\n  - Neonatal hypoglycemia: weight $0.5$.\n  - Maternal hyperglycemia requiring temporary insulin therapy: weight $0.1$.\n  - Clinical chorioamnionitis: weight $1.5$.\n\nDefine the composite expected benefit $B$ of treating now (if delivery occurs within $7$ days) as the sum, over the severe neonatal outcomes, of the product of baseline risk, relative risk reduction, and severity weight. Define the composite expected harm $H$ of treating now (if delivery does not occur within $7$ days) as the sum, over the adverse outcomes, of the product of absolute risk increase and severity weight.\n\nLet $p$ be the clinician’s posterior probability that delivery will occur within $7$ days. Using first principles of expected utility, construct the threshold decision inequality $p \\cdot B - (1-p) \\cdot H > 0$ for treating now, and solve for the break-even probability $p$ at which the clinician is indifferent between treating and not treating. Compute $B$ and $H$ from the data above and then determine the break-even $p$. Express the final $p$ as a decimal fraction and round your answer to four significant figures.",
            "solution": "The problem has been validated as scientifically grounded, well-posed, objective, and internally consistent. All necessary data and definitions are provided to arrive at a unique, meaningful solution. There are no contradictions, ambiguities, or violations of scientific principles. Therefore, a solution will be provided.\n\nThe problem requires us to determine the break-even probability $p$ for administering antenatal corticosteroids. This probability represents the point of indifference, where the expected utility of treating is equal to the expected utility of not treating. The decision framework is based on the inequality $p \\cdot B - (1-p) \\cdot H > 0$, where $p$ is the probability of delivery within $7$ days, $B$ is the composite expected benefit if delivery occurs within $7$ days, and $H$ is the composite expected harm if delivery does not occur within $7$ days.\n\nFirst, we must calculate the composite expected benefit, $B$. The problem defines $B$ as the sum of the product of baseline risk, relative risk reduction, and severity weight for each of the three severe neonatal outcomes. The relative risk reduction (RRR) is calculated as $1 - RR$, where $RR$ is the relative risk.\n\nLet $R_{resp}$, $R_{ivh}$, and $R_{death}$ be the baseline risks for severe neonatal respiratory morbidity, Grade III/IV IVH, and neonatal death, respectively.\nLet $RR_{resp}$, $RR_{ivh}$, and $RR_{death}$ be the corresponding relative risks.\nLet $W_{resp}$, $W_{ivh}$, and $W_{death}$ be the corresponding severity weights.\n\nThe given values are:\n$R_{resp} = 0.30$, $RR_{resp} = 0.65$, $W_{resp} = 1.0$\n$R_{ivh} = 0.05$, $RR_{ivh} = 0.55$, $W_{ivh} = 3.0$\n$R_{death} = 0.04$, $RR_{death} = 0.70$, $W_{death} = 5.0$\n\nThe contribution to $B$ from each outcome is calculated as $R \\times (1-RR) \\times W$.\nFor severe neonatal respiratory morbidity:\n$$B_{resp} = R_{resp} \\times (1 - RR_{resp}) \\times W_{resp} = 0.30 \\times (1 - 0.65) \\times 1.0 = 0.30 \\times 0.35 \\times 1.0 = 0.105$$\nFor Grade III/IV IVH:\n$$B_{ivh} = R_{ivh} \\times (1 - RR_{ivh}) \\times W_{ivh} = 0.05 \\times (1 - 0.55) \\times 3.0 = 0.05 \\times 0.45 \\times 3.0 = 0.0675$$\nFor neonatal death:\n$$B_{death} = R_{death} \\times (1 - RR_{death}) \\times W_{death} = 0.04 \\times (1 - 0.70) \\times 5.0 = 0.04 \\times 0.30 \\times 5.0 = 0.060$$\nThe total composite expected benefit $B$ is the sum of these contributions:\n$$B = B_{resp} + B_{ivh} + B_{death} = 0.105 + 0.0675 + 0.060 = 0.2325$$\n\nNext, we calculate the composite expected harm, $H$. This is defined as the sum of the product of the absolute risk increase and severity weight for each adverse outcome that occurs when delivery is not within $7$ days.\n\nLet $ARI_{hypo}$, $ARI_{hyper}$, and $ARI_{chorio}$ be the absolute risk increases for neonatal hypoglycemia, maternal hyperglycemia, and clinical chorioamnionitis, respectively.\nLet $W_{hypo}$, $W_{hyper}$, and $W_{chorio}$ be the corresponding severity weights.\n\nThe given values are:\n$ARI_{hypo} = 0.08$, $W_{hypo} = 0.5$\n$ARI_{hyper} = 0.06$, $W_{hyper} = 0.1$\n$ARI_{chorio} = 0.02$, $W_{chorio} = 1.5$\n\nThe contribution to $H$ from each outcome is calculated as $ARI \\times W$.\nFor neonatal hypoglycemia:\n$$H_{hypo} = ARI_{hypo} \\times W_{hypo} = 0.08 \\times 0.5 = 0.040$$\nFor maternal hyperglycemia:\n$$H_{hyper} = ARI_{hyper} \\times W_{hyper} = 0.06 \\times 0.1 = 0.006$$\nFor clinical chorioamnionitis:\n$$H_{chorio} = ARI_{chorio} \\times W_{chorio} = 0.02 \\times 1.5 = 0.030$$\nThe total composite expected harm $H$ is the sum of these contributions:\n$$H = H_{hypo} + H_{hyper} + H_{chorio} = 0.040 + 0.006 + 0.030 = 0.076$$\n\nThe break-even probability $p$ is the value at which the clinician is indifferent, meaning the net expected utility is zero. We set the decision inequality to an equality:\n$$p \\cdot B - (1-p) \\cdot H = 0$$\nWe solve this equation for $p$:\n$$p \\cdot B = (1-p) \\cdot H$$\n$$p \\cdot B = H - p \\cdot H$$\n$$p \\cdot B + p \\cdot H = H$$\n$$p (B + H) = H$$\n$$p = \\frac{H}{B + H}$$\nSubstituting the calculated values for $B$ and $H$:\n$$p = \\frac{0.076}{0.2325 + 0.076} = \\frac{0.076}{0.3085}$$\nPerforming the division gives:\n$$p \\approx 0.2463533225...$$\nThe problem requires the final answer to be rounded to four significant figures. The fifth significant digit is $5$, so we round up the fourth.\n$$p \\approx 0.2464$$\nThis means that if the clinician's estimated probability of delivery within $7$ days is greater than $0.2464$, the expected utility of administering corticosteroids is positive, and treatment is the preferred action.",
            "answer": "$$\\boxed{0.2464}$$"
        }
    ]
}